Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Hexabody-CD38, a Novel CD38 Antibody with a Hexamerization Enhancing Mutation, Demonstrates Enhanced Complement-Dependent Cytotoxicity and Shows Potent Anti-Tumor Activity in Preclinical Models of Hematological Malignancies

Bart ECG De Goeij, PhD, Maarten L Janmaat, PhD, Grietje Andringa, Laurens Kil, Berris Van Kessel, Kristine A. Frerichs, MD, Andreas Lingnau, Andreas Freidig, Tuna Mutis, MD PhD, A. Kate Sasser, Esther C. W. Breij, Niels W. C. J. Van De Donk, MD PhD, Tahamtan Ahmadi, David Satijn

Blood (2019) 134 (Supplement_1): 3106.

https://doi.org/10.1182/blood-2019-125788

Published: 2019

Journal Articles

Daratumumab in Combination with Lenalidomide Plus Dexamethasone Results in Persistent Natural Killer (NK) Cells with a Distinct Phenotype and Expansion of Effector Memory T-Cells in Pollux, a Phase 3 Randomized Study

Blood (2017) 130 (Supplement 1): 3124.

https://doi.org/10.1182/blood.V130.Suppl_1.3124.3124

Published: 2017

Journal Articles

High-Parameter Mass Cytometry (CyTOF) Evaluation of Relapsed/Refractory Multiple Myeloma (MM) Pts (Pts) Treated with Daratumumab Supports Immune Modulation As a Novel Mechanism of Action

Homer Adams, III, PhD, Frederik Stevenaert, Jakub Krejcik, Koen Van der Borght, Tineke Casneuf, Tina Smets, Jaime Bald, Yann Abraham, Hugo Ceulemans, Greet Vanhoof, Tahamtan Ahmadi, MD, Saad Z Usmani, MD, Torben Plesner, Professor, Sagar Lonial, MD FACP, Berris van Kessel-Welmers, Henk M. Lokhorst, MD PhD, Tuna Mutis, MD PhD, Niels W.C.J. van de Donk, MD PhD, A. Kate Sasser

Blood (2016) 128 (22): 4521.

https://doi.org/10.1182/blood.V128.22.4521.4521

Published: 2016

Journal Articles

Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma

Blood (2016) 128 (19): 2297–2306.

https://doi.org/10.1182/blood-2016-07-729236

Published: 2016

Includes: Supplemental data

Journal Articles

CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma

Inger S. Nijhof, Tineke Casneuf, Jeroen van Velzen, Berris van Kessel, Amy E. Axel, Khaja Syed, Richard W. J. Groen, Mark van Duin, Pieter Sonneveld, Monique C. Minnema, Sonja Zweegman, Christopher Chiu, Andries C. Bloem, Tuna Mutis, Henk M. Lokhorst, A. Kate Sasser, Niels W. C. J. van de Donk

Blood (2016) 128 (7): 959–970.

https://doi.org/10.1182/blood-2016-03-703439

Published: 2016

Includes: Supplemental data

Journal Articles

Modulation of CD38 Expression Levels on Multiple Myeloma Tumor Cells By All- Trans Retinoic Acid Improves the Efficacy of the Anti-CD38 Monoclonal Antibody Daratumumab

Inger S. Nijhof, MD, Henk M. Lokhorst, MDPhD, Berris van Kessel, Richard W.J. Groen, PhD, Anton C. Martens, PhD, Parul Doshi, PhD, Saskia K. Klein, MDPhD, Tuna Mutis, MDPhD, Kate Sasser, Niels W.C.J. van de Donk, MDPhD

Blood (2014) 124 (21): 2096.

https://doi.org/10.1182/blood.V124.21.2096.2096

Published: 2014

Journal Articles

CD38-Targeted Immunochemotherapy Of Multiple Myeloma: Preclinical Evidence For Its Combinatorial Use In Lenalidomide and Bortezomib Refractory/Intolerant MM Patients

Inger S. Nijhof, MD, Willy A. Noort, PhD, Jeroen Lammerts van Bueren, PhD, Berris van Kessel, Joost M. Bakker, PhD, Paul W.H.I. Parren, PhD, Richard W.J. Groen, PhD, Niels W.C.J. van de Donk, MD, PhD, Henk Lokhorst, Tuna Mutis, MD, PhD, Anton Martens, PhD

Blood (2013) 122 (21): 277.

https://doi.org/10.1182/blood.V122.21.277.277

Published: 2013

Journal Articles

Phase 1/2 Trial Of Lenalidomide In Combination With Cyclophosphamide and Prednisone (REP) In Patients With Lenalidomide-Refractory Multiple Myeloma (REPEAT-study)

Inger S. Nijhof, MD, Sonja Zweegman, MD PhD, Mark-David Levin, MD PhD, Harry R. Koene, MD PhD, Aart Beeker, MD, Andries C. Bloem, PhD, Gerard M.J. Bos, MD PhD, Laura M. Faber, MD PhD, Saskia K. Klein, MD PhD, Evert-Jan F.M. de Kruijf, MD, Ellen van der Spek, MD PhD, Shulamiet Wittebol, MD PhD, Jeroen F. van Velzen, Berris van Kessel, Tuna Mutis, MD, PhD, Pieter Sonneveld, MD, Ph.D, Henk Lokhorst, Niels W.C.J. van de Donk, MD, PhD

Blood (2013) 122 (21): 287.

https://doi.org/10.1182/blood.V122.21.287.287

Published: 2013

Journal Articles

Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Refractory Patient-Derived Multiple Myeloma Cells, Growing in a Novel Humanized Mouse MM Model

Willy A Noort, PhD, Richard W.J. Groen, PhD, Reinier Raymakers, MD, PhD, Linda Aalders, Frans M Hofhuis, Berris Van Kessel, Jeroen F Van Velzen, Joost de Bruijn, PhD, Huipin Yuan, PhD, Jeroen Lammerts van Bueren, PhD, Andries C Bloem, PhD, Paul W.H.I. Parren, PhD, Henk Lokhorst, MD, Tuna Mutis, MD PhD, Anton C.M. Martens, PhD

Blood (2012) 120 (21): 940.

https://doi.org/10.1182/blood.V120.21.940.940

Published: 2012

Journal Articles

Towards CD38-Targeted Immunochemotherapy of Multiple Myeloma: Significant Improvement of Anti-Myeloma Effects of Lenalidomide, Bortezomib and Dexamethason by CD38-Specific Antibody Daratumumab, Even in Chemotherapy Resistant/Intolerant Patients

Inger S. Nijhof, MD, Jeroen Lammerts van Bueren, Berris van Kessel, Michel de Weers, Joost M Bakker, PhD, Paul W. H. I. Parren, PhD, Henk Lokhorst, MD, PhD, Tuna Mutis, MD PhD

Blood (2012) 120 (21): 4988.

https://doi.org/10.1182/blood.V120.21.4988.4988

Published: 2012

Journal Articles

Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma

Blood (2012) 120 (3): e9–e16.

https://doi.org/10.1182/blood-2012-03-414920

Published: 2012

Includes: Supplemental data

Journal Articles

Reconstructing the Human Hematopoietic Niche: Opportunities for Studying Normal and Malignant Hematopoiesis,

Richard W Groen, PhD, Willy A Noort, PhD, Reinier Raymakers, MD, PhD, Henk-Jan Prins, Msc, Linda Aalders, Frans M Hofhuis, Berris van Kessel, Petra Moerer, Henk Rozemuller, PhD, Jan J. Schuringa, PhD, Joost de Bruijn, PhD, Michel de Weers, PhD, Paul W.H.I. Parren, PhD, Henk M. Lokhorst, MD, Tuna Mutis, MD PhD, Anton CM Martens, PhD

Blood (2011) 118 (21): 3412.

https://doi.org/10.1182/blood.V118.21.3412.3412

Published: 2011

Journal Articles

The Human CD38 Monoclonal Antibody Daratumumab Improves the Anti-Myeloma Effect of Lenalidomide with Dexamethasone in Vitro

Michel de Weers, PhD, Michael van der Veer, Berris van Kessel, Joost M Bakker, PhD, Shulamiet Wittebol, MD, Paul WHI Parren, PhD, Henk M. Lokhorst, MD, Tuna Mutis, MD PhD

Blood (2011) 118 (21): 5106.

https://doi.org/10.1182/blood.V118.21.5106.5106

Published: 2011

Journal Articles

Synergistic Action of the Human Inhibitory KIR Antibody IPH2102, and the Human CD38 Antibody Daratumumab to Enhance the Lysis of Primary Multiple Myeloma (MM) Cells in the Bone Marrow Mononuclear Cells (MNCs) From Myeloma Patients

Inger S. Nijhof, MD, Michel de Weers, PhD, Pascale Andre, PhD, Berris van Kessel, Henk M. Lokhorst, MD, Paul W.H.I. Parren, PhD, Yannis Morel, PhD, Tuna Mutis, MD PhD

Blood (2011) 118 (21): 1865.

https://doi.org/10.1182/blood.V118.21.1865.1865

Published: 2011

Journal Articles

A Unique New Humanized Mouse Model for Multiple Myeloma (MM): Opportunities for Studying MM In Its Natural Environment and for Preclinical Testing

Richard W Groen, Frans M Hofhuis, Linda Aalders, Berris van Kessel, Michel de Weers, PhD, Tuna Mutis, MD, PhD, Henk Lokhorst, MD, PhD, Anton C Martens, PhD

Blood (2010) 116 (21): 981.

https://doi.org/10.1182/blood.V116.21.981.981

Published: 2010

Journal Articles

In Vitro and In Vivo Efficacy of CD38 Directed Therapy with Daratumumab In the Treatment of Multiple Myeloma

Richard W Groen, Michael van der Veer, Frans M Hofhuis, Berris van Kessel, Michel de Weers, PhD, Paul W.H.I. Parren, PhD, Henk M Lokhorst, MD, PhD, Tuna Mutis, MD, PhD, Anton Martens, PhD

Blood (2010) 116 (21): 3058.

https://doi.org/10.1182/blood.V116.21.3058.3058

Published: 2010

Journal Articles

Towards Effective Immunotherapy of Multiple Myeloma: Enhanced Elimination of Myeloma Cells by Combination of Lenalidomide with the Human CD38 Monoclonal Antibody Daratumumab

Michael S. van der Veer, Michel de Weers, Berris van Kessel, Shulamiet Wittebol, Joost M Bakker, Paul W.H.I. Parren, Henk M Lokhorst, Tuna Mutis, MD, PhD

Blood (2010) 116 (21): 3059.

https://doi.org/10.1182/blood.V116.21.3059.3059

Published: 2010

Journal Articles

Improved Myeloma Targeting by Combination of the Human Anti-CD38 Antibody Daratumumab with Lenalidomide and Bortezomib

Michael S. van der Veer, Michel de Weers, Berris van Kessel, Joost M Bakker, Shulamiet Wittebol, Paul W.H.I. Parren, Henk M Lokhorst, Tuna Mutis, MD, PhD

Blood (2010) 116 (21): 3030.

https://doi.org/10.1182/blood.V116.21.3030.3030

Published: 2010

Journal Articles

The Humanized Multiple Myeloma Mouse Model: Opportunities for Studying the Pathogenesis of MM in Its Natural Environment.

Richard W.J. Groen, Frans M. Hofhuis, Henk-Jan Prins, Henk Rozemuller, PhD, Berris van Kessel, Michel de Weers, PhD, Henk Lokhorst, MD, PhD, Anton C.M. Martens, PhD

Blood (2009) 114 (22): 1847.

https://doi.org/10.1182/blood.V114.22.1847.1847

Published: 2009

Journal Articles

Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels

Niels W. C. J. van de Donk, Marloes M. J. Kamphuis, Berris van Kessel, Henk M. Lokhorst, Andries C. Bloem

Blood (2003) 102 (9): 3354–3362.

https://doi.org/10.1182/blood-2003-03-0970

Published: 2003

NARROW

Hexabody-CD38, a Novel CD38 Antibody with a Hexamerization Enhancing Mutation, Demonstrates Enhanced Complement-Dependent Cytotoxicity and Shows Potent Anti-Tumor Activity in Preclinical Models of Hematological Malignancies

Daratumumab in Combination with Lenalidomide Plus Dexamethasone Results in Persistent Natural Killer (NK) Cells with a Distinct Phenotype and Expansion of Effector Memory T-Cells in Pollux, a Phase 3 Randomized Study

High-Parameter Mass Cytometry (CyTOF) Evaluation of Relapsed/Refractory Multiple Myeloma (MM) Pts (Pts) Treated with Daratumumab Supports Immune Modulation As a Novel Mechanism of Action

Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma

CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma

Modulation of CD38 Expression Levels on Multiple Myeloma Tumor Cells By All- Trans Retinoic Acid Improves the Efficacy of the Anti-CD38 Monoclonal Antibody Daratumumab

CD38-Targeted Immunochemotherapy Of Multiple Myeloma: Preclinical Evidence For Its Combinatorial Use In Lenalidomide and Bortezomib Refractory/Intolerant MM Patients

Phase 1/2 Trial Of Lenalidomide In Combination With Cyclophosphamide and Prednisone (REP) In Patients With Lenalidomide-Refractory Multiple Myeloma (REPEAT-study)

Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Refractory Patient-Derived Multiple Myeloma Cells, Growing in a Novel Humanized Mouse MM Model

Towards CD38-Targeted Immunochemotherapy of Multiple Myeloma: Significant Improvement of Anti-Myeloma Effects of Lenalidomide, Bortezomib and Dexamethason by CD38-Specific Antibody Daratumumab, Even in Chemotherapy Resistant/Intolerant Patients

Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma

Reconstructing the Human Hematopoietic Niche: Opportunities for Studying Normal and Malignant Hematopoiesis,

The Human CD38 Monoclonal Antibody Daratumumab Improves the Anti-Myeloma Effect of Lenalidomide with Dexamethasone in Vitro

Synergistic Action of the Human Inhibitory KIR Antibody IPH2102, and the Human CD38 Antibody Daratumumab to Enhance the Lysis of Primary Multiple Myeloma (MM) Cells in the Bone Marrow Mononuclear Cells (MNCs) From Myeloma Patients

A Unique New Humanized Mouse Model for Multiple Myeloma (MM): Opportunities for Studying MM In Its Natural Environment and for Preclinical Testing

In Vitro and In Vivo Efficacy of CD38 Directed Therapy with Daratumumab In the Treatment of Multiple Myeloma

Towards Effective Immunotherapy of Multiple Myeloma: Enhanced Elimination of Myeloma Cells by Combination of Lenalidomide with the Human CD38 Monoclonal Antibody Daratumumab

Improved Myeloma Targeting by Combination of the Human Anti-CD38 Antibody Daratumumab with Lenalidomide and Bortezomib

The Humanized Multiple Myeloma Mouse Model: Opportunities for Studying the Pathogenesis of MM in Its Natural Environment.

Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only